AstraZeneca Falls 9% After Wainua Heart Drug Misses Primary Endpoint
AZN•AstraZeneca shares tumbled 9% after its Wainua heart failure drug failed to meet the primary endpoint in a late-stage trial. The setback halts planned regulatory submissions and intensifies scrutiny over the therapy’s expected contribution to cardiovascular revenue growth.
1. Trial Failure Details
The Wainua heart failure candidate, positioned for a pivotal late-stage trial, failed to achieve its primary endpoint of reducing major adverse cardiovascular events. The neutral outcome disrupts AstraZeneca’s development timeline and forces a reassessment of the drug’s clinical viability.
2. Market Reaction and Outlook
Following the trial announcement, AstraZeneca shares plunged 9%, reflecting investor concern over the lost milestone and delayed regulatory filings. Analysts now question the impact on the company’s cardiovascular sales projections and may adjust pipeline valuations accordingly.
